Hindustan Unilever Limited (HUL) announced two strategic transactions on February 12, 2026. HUL acquired the remaining 49% stake in Zywie Ventures Private Limited (OZiva) for INR 824 Crores, making it a wholly-owned subsidiary to strengthen its Health & Wellbeing portfolio. Concurrently, HUL sold its 19.8% minority stake in Nutritionalab Private Limited to USV Private Limited for INR 307 Crores.
HUL Executes Dual Strategic Moves in Health & Wellbeing
Hindustan Unilever Limited (HUL) has approved two significant transactions on February 12, 2026, as part of its strategy focusing on “fewer, bigger bets” within its Health & Wellbeing (H&W) business segment.
Acquisition of Full Control in OZiva
HUL has approved the acquisition of the balance 49% shareholding in Zywie Ventures Private Limited (“Target” or “OZiva”) for a cash consideration of INR 824 Crores. This acquisition will result in Zywie, and its wholly-owned subsidiary Zenherb Labs Private Limited, becoming wholly owned subsidiaries of HUL.
- The Target, incorporated in 2013, is involved in manufacturing and selling Vitamins, Minerals and Supplements, Beauty and Personal Care, and Protein products.
- The turnover for the Target was INR 257.67 Crores for FY 2024-25.
- The transaction is expected to be completed by March 31, 2026.
- This move is intended to unlock the next phase of growth for the fast-growing consumer space where OZiva has shown strong performance, scaling to approximately Rs. 480 crores in 2025 with a growth of c. 130% CAGR in the last two years.
Divestment of Nutritionalab Stake
In alignment with its portfolio transformation strategy, HUL’s Board also approved the sale of its entire 19.8% shareholding in Nutritionalab Private Limited.
- The buyer is USV Private Limited.
- The sale consideration received is INR 307 Crores, subject to customary closing adjustments.
- Nutritionalab is classified as a Joint Venture and its revenue from operations for FY 2024-25 was INR 118.48 crores. Under the equity method of accounting used by HUL, this revenue was not recognized in HUL’s consolidated results.
- The transaction does not fall within related party transactions and is being executed on an arm’s length basis.
CEO Statement and Outlook
Priya Nair, CEO and Managing Director of HUL, stated that taking full ownership of OZiva reflects HUL’s commitment to the Health & Wellbeing sector, leveraging the company’s strengths in science, distribution, and market development to scale purpose-led brands.
Both transactions are subject to the fulfillment of terms and conditions specified in the definitive transaction documents.
Source: BSE
